公司資料
NuCana plc 股價、新聞與催化劑
- 股票代碼:
- NCNA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom
股票表現
1.52 USD (-0.65%)
收盤價
最後更新: 2026年8月21日
8.62M USD
市值
股價為何變動
As of Aug 21, 2026, NCNA closed down 0.65% at $1.52. No new same-company headline was identified in the current news window.
公司概覽
ProTide Oncology Company
NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells.
NUC-7738
NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor microenvironment. It is being evaluated with pembrolizumab in PD-1-inhibitor-resistant melanoma.
NUC-3373
NUC-3373 is a targeted thymidylate-synthase inhibitor designed to overcome pharmacologic limitations of established fluoropyrimidine therapies.
Combination Development
NuCana is evaluating tumor types and drug combinations that could support future registrational strategies for both NUC-7738 and NUC-3373.
未來催化劑
- Final data from the Phase 2 NuTide:701 expansion study of NUC-7738 in melanoma during 2026.
- FDA guidance on a potential registrational strategy for NUC-7738 in melanoma during 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。